TOPIGEN raises $26 million to accelerate clinical trials

Montreal-based TOPIGEN Pharmaceuticals Inc has secured $26 million in series C financing to accelerate Phase II clinical programs related to its lead products for respiratory therapeutics. The total raised to date from all sources is now $75 million and more may be added to the C series. Investors in the latest round are NovaQuest, MMV Financial Inc, BDC Venture Capital, Desjardins Venture Capital, Caisse de Depot et Placement du Quebec, T2C2/BIO 2000 and Lothian Partners 27. TOPIGEN therapeutics suppress pulmonary inflammation by delivering drugs directly to the site of cellular action in the lung through inhalation. Its two lead products target asthma and chronic obstructive pulmonary disease….